Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension - Summary - MDSpire
Advertisement
Dapagliflozin and linagliptin combination therapy improves time in range and reverses hepatic steatosis in patients with type 2 diabetes and hypertension
To evaluate the effects of dapagliflozin combined with linagliptin on glycemic control and specific organ protection parameters in patients with Type 2 diabetes and hypertension.
Key Findings:
Combination therapy achieved superior TIR (94.86%) compared to monotherapies (~80%) and control (81.44%; P<0.001).
Significant reductions in HbA1c (to 5.52%), fasting glucose, blood pressure (systolic to 124 mmHg), triglycerides (to 0.72 mmol/L), liver enzymes (ALT to 9.74 U/L), and UACR (to 7.36 mg/g; all P<0.001).
Higher eGFR (to 122.41 mL/min/1.73m²; all P<0.05 vs. others).
TIR correlated with improved hepatorenal markers.
Interpretation:
The combination of dapagliflozin and linagliptin significantly improves glycemic stability and organ protection in patients with T2DM and hypertension.
Limitations:
Observational study design limits causal inferences.
Short follow-up duration may not capture long-term effects, potentially underestimating the therapy's benefits.
Conclusion:
Dapagliflozin-linagliptin combination therapy is effective for managing T2DM with hypertension, enhancing glycemic control and organ function.
